LinkedIn

Clinical Trial Protocol with Gen AI: Simplifying Protocol Generation for Better Results

With clinical trials becoming increasingly complex, nearly two-thirds fall short of their primary objectives due to issues like poor design, flawed statistical approaches, unrealistic operational demands, limited stakeholder engagement, and regulatory challenges.

The urgency for efficient and precise protocol development has never been greater. Generative AI is a game changer in this critical phase. By automating and optimizing protocol creation, AI accelerates timelines, enhances accuracy, and significantly lowers costs, paving the way for more successful trials.

Understanding a Clinical Trial Protocol

A protocol is an all-inclusive blueprint, describing each detail of the study. It is a critical document that defines how a clinical trial will be executed. It includes key components

 

Clinical Trial Protocol: A Complete Breakdown

The protocol serves as a roadmap for the trial, ensuring that it adheres to regulatory standards, safeguards participant safety, and provides a clear framework for all involved parties, including researchers, sponsors, and regulatory authorities.

What is an eProtocol?

An eProtocol is an electronically generated version of the clinical trial protocol. Digitization of the protocol creation allows for better collaboration, version control, and efficiency. By incorporating Large Language Models (LLMs) and Gen AI, trial data from relevant sources can be extracted and used in accurately filling the protocol document’s necessary sections of the protocol document thus reducing the manual effort, time, and resources spent.

How AI is Advancing eProtocol Design

Developing research protocols typically takes 160–220 hours due to its complexity and stakeholder collaboration. AI tools like eProtocol reduce this to just 1 day for generating content, with 1–2 weeks for review and styling, streamlining the process and minimizing delays.

Training on Real-World Protocols

AI-powered tools are reshaping protocol development by leveraging data-driven insights and continuous learning for greater accuracy and efficiency.

  • Data Collection: AI tools are trained on extensive datasets of clinical trial protocols, including study objectives, endpoints, methodologies, and regulatory requirements. By learning from these datasets, AI generates protocol components that meet industry standards and address common challenges. GenAI, requiring less data than traditional ML models, can be fine-tuned with just a few past protocols to deliver precise, industry-standard results.
  • Continuous Learning: AI systems can continuously improve by learning from new data and user feedback. This iterative learning process helps the AI adapt to evolving industry standards and practices.

Standardized Templates and Frameworks

AI tools often utilize standardized templates to ensure consistency and compliance across protocols. These templates are developed by industry organizations to provide a framework that aligns with regulatory requirements and best practices.

Template Utilization: The AI tool incorporates standardized templates from industry leaders like TransCelerate to efficiently structure protocols. Utilizing these pre-defined frameworks ensures that all essential elements are included, properly formatted, and fully aligned with industry best practices and regulatory standards.

Automated Document Generation

The process of generating a protocol involves several steps that can be automated using AI:

Initial Draft Creation: Users provide a protocol synopsis, which the AI tool uses to generate the initial draft of the protocol. The synopsis includes key details such as study objectives, endpoints, and methodologies.

Text Generation: The AI tool automatically generates text for each section of the protocol based on the input synopsis. The AI can produce coherent and contextually appropriate text, ensuring that all necessary information is included.

Formatting and Structuring: The tool formats the generated content according to standardized guidelines, ensuring that the protocol is well-structured and compliant with regulatory requirements.

Collaboration and Version Control

After the initial protocol is generated, users can collaborate within the tool to edit and refine each section. The tool allows multiple users to access and edit the protocol simultaneously. Users can make iterative changes to the protocol, incorporating feedback and adjustments. The AI tool supports this process by tracking changes and maintaining version control.

Customization

Despite the use of standardized templates, AI tools offer flexibility for customization. Researchers can tailor the protocol to fit the unique requirements of their trial, combining the benefits of standardization with the need for specific adaptations.

The Impact of AI on Protocol Generation

AI-driven eProtocol generation represents a significant technological advancement in clinical trial protocol development. By leveraging machine learning, utilizing standardized templates, and automation, these tools are advancing the creation of high-quality protocols, enhancing efficiency, and reducing errors. As AI technology continues to evolve, its role in clinical research is expanding, offering new opportunities for improving the design and execution of clinical trials.

Clinion’s AI: Transforming Protocol Design

Clinion leads the way in clinical trials, driving innovation with AIML and GenAI solutions. By utilizing GenAI tools, it can generate around 60% of a full study protocol from just a brief synopsis, leveraging extensive training on real-world protocols. The tool employs the standardized TransCelerate template to automatically generate and format each protocol section while enabling effective collaboration for reviewing and refining documents. With these advancements, Clinion is not just streamlining trial processes; it’s setting a new standard for efficiency and accuracy in clinical research, ultimately enhancing patient outcomes and accelerating the journey to clinical breakthroughs.

Get in touch with our product experts today to learn more